CD8+ T cell states in human cancer: insights from single-cell analysis (original) (raw)

• Clemente, C. G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303–1310 (1996).
  CAS PubMed Google Scholar
• Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
  CAS PubMed Google Scholar
• Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
  CAS PubMed Google Scholar
• Fridman, W. H., Pagès, F., Saut’s-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
  CAS PubMed Google Scholar
• Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
  CAS PubMed PubMed Central Google Scholar
• Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
  CAS PubMed PubMed Central Google Scholar
• Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
  CAS PubMed PubMed Central Google Scholar
• Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
  CAS PubMed PubMed Central Google Scholar
• Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
  CAS PubMed Google Scholar
• Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl Med. 6, 254ra128 (2014).
  PubMed Google Scholar
• Robert, L. et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer Res. 20, 2424–2432 (2014).
  CAS PubMed PubMed Central Google Scholar
• Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl Med. 6, 238ra70 (2014).
  PubMed PubMed Central Google Scholar
• Robert, L. et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 3, e29244 (2014).
  PubMed PubMed Central Google Scholar
• Barnes, T. A. & Amir, E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 117, 451–460 (2017).
  CAS PubMed PubMed Central Google Scholar
• Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
  CAS PubMed PubMed Central Google Scholar
• Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
  CAS PubMed PubMed Central Google Scholar
• Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).
  CAS PubMed PubMed Central Google Scholar
• Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
  CAS PubMed PubMed Central Google Scholar
• Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696–701 (2019).
  CAS PubMed PubMed Central Google Scholar
• Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016). The first single-cell transcriptome and TCR analysis of the TME in human melanoma, dissecting the major T cell states and tumour-specific programmes.
  CAS PubMed PubMed Central Google Scholar
• Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775–789.e18 (2019). Single-cell transcriptome and TCR analysis in human melanoma describing a dysfunctional axis made up of cells that are transcriptionally related and show TCR sharing, as well as a separate cytotoxic population. The dysfunctional T cells identified contain a highly proliferative subset and are indicative of the presence of a tumour-reactive T cell repertoire.
  CAS PubMed Google Scholar
• Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2018). Single-cell transcriptome analysis in human melanoma indicating that TCF7 -expressing T cells in human cancer are associated with response to ICB. Furthermore, the study shows that CD39 − and TIM3 − T cells display reactivity against mouse colon carcinoma cells in the presence of anti-PD1.
  CAS PubMed PubMed Central Google Scholar
• Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290–1297 (2011).
  CAS PubMed PubMed Central Google Scholar
• Baitsch, L. et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350–2360 (2011).
  CAS PubMed PubMed Central Google Scholar
• Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 1–11 (2018). This study defines a T cell subset in human NSCLC with high expression of PD1 that is enriched for tumour reactivity, that expresses markers of T cell activation and that appears predictive of clinical response to anti-PD1 therapy.
  Google Scholar
• Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade. Proc. Natl Acad. Sci. USA 105, 15016–15021 (2008).
  CAS PubMed PubMed Central Google Scholar
• Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911–4927 (2003).
  CAS PubMed PubMed Central Google Scholar
• Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342–1356.e16 (2017). Single-cell transcriptome and TCR analysis of T cells in HCC showing the distribution and connectivity between T cell states in tumour tissue, adjacent normal tissue and blood, and that also provides evidence for the presence of cell state diversity within T cell clones.
  CAS PubMed Google Scholar
• Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–985 (2018). Single-cell transcriptome analysis of T cells in NSCLC, adjacent normal tissue and blood showing the distribution of T cell states in these tissues and their relatedness based on TCR sharing between cell states inside and outside the tumour. Moreover, this study provides evidence for dysfunctionality as a gradual state.
  CAS PubMed Google Scholar
• Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019). Single cell transcriptome and TCR analysis of T cells in human BCC suggest the presence of novel T cell clonotypes within the dysfunctional (‘exhausted’) compartment after ICB.
  CAS PubMed PubMed Central Google Scholar
• Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268–272 (2018). Single-cell transcriptome and TCR analysis of T cells in microsatellite-stable and microsatellite-instable colorectal tumours addressing the clonotypic relationships between intratumoural dysfunctional cells and T cells with other cell states that reside in the tumour, normal tissue or blood.
  CAS PubMed Google Scholar
• Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308.e36 (2018). Single-cell transcriptome analysis of immune cells in human breast cancer demonstrating that intratumoural T cells reside along a continuum that is driven by activation and terminal differentiation. In addition, cell state diversity is shown both between and within T cell clones.
  CAS PubMed PubMed Central Google Scholar
• Clarke, J. et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J. Exp. Med. 216, 2128–2149 (2019). Single-cell transcriptome analysis of T cells in human NSCLC describing a PD1-expressing and TIM3-expressing T RM cell subset that contains a highly proliferative subset and is enriched in lesions of patients responding to anti-PD1 therapy.
  CAS PubMed PubMed Central Google Scholar
• Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986–993 (2018). Single-cell transcriptome analysis of T cells in two human breast cancer samples characterizing T RM cells that express, among other genes, inhibitory receptor genes such as PDCD1 and CTLA4.
  CAS PubMed Google Scholar
• Fehlings, M. et al. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. Nat. Commun. 8, 562 (2017).
  CAS PubMed PubMed Central Google Scholar
• Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749.e18 (2017).
  CAS PubMed PubMed Central Google Scholar
• Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).
  CAS PubMed Google Scholar
• Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330–1345.e18 (2019).
  CAS PubMed PubMed Central Google Scholar
• Salerno, F. & Wolkers, M. C. T-cells require post-transcriptional regulation for accurate immune responses. Biochem. Soc. Trans. 43, 1201–1207 (2015).
  CAS PubMed Google Scholar
• Salerno, F. et al. Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells. Oncoimmunology 8, e1532762 (2019).
  PubMed Google Scholar
• Dieu-Nosjean, M. C. et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271, 260–275 (2016).
  CAS PubMed Google Scholar
• Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019).
  PubMed Google Scholar
• Kunz, D. J., Gomes, T. & James, K. R. Immune cell dynamics unfolded by single-cell technologies. Front. Immunol. 9, 1435 (2018).
  PubMed PubMed Central Google Scholar
• Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019). A mouse melanoma study showing the importance of a low dysfunctional (‘progenitor exhausted’) T cell population marked by TCF1 expression and required for response to anti-PD1 therapy.
  CAS PubMed PubMed Central Google Scholar
• Lanitis, E., Dangaj, D., Irving, M. & Coukos, G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann. Oncol. 28, xii18–xii32 (2017).
  CAS PubMed Google Scholar
• Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89–94 (2019). Unbiased analysis of the tumour reactivity of TCRs in human cancer lesions providing formal evidence that human colorectal and ovarian tumours contain high proportions of bystander T cells.
  CAS PubMed Google Scholar
• Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018). This study demonstrates the presence of virus-specific bystander T cells in human lung and colorectal tumours. Intratumoural bystander T cells were characterized by a lack of CD39 expression, suggesting that CD39 can be used to help distinguish tumour-reactive T cells from bystander cells.
  CAS PubMed Google Scholar
• Erkes, D. A. et al. Virus-specific CD8+ T cells infiltrate melanoma lesions and retain function independently of PD-1 expression. J. Immunol. 198, 2979–2988 (2017).
  CAS PubMed Google Scholar
• Kvistborg, P. et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients. Oncoimmunology 1, 409–418 (2012).
  PubMed PubMed Central Google Scholar
• Rosato, P. C. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat. Commun. 10, 567 (2019).
  CAS PubMed PubMed Central Google Scholar
• Pasetto, A. et al. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol. Res. 4, 734–743 (2016).
  CAS PubMed PubMed Central Google Scholar
• Schietinger, A. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389–401 (2016).
  CAS PubMed PubMed Central Google Scholar
• Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).
  CAS PubMed PubMed Central Google Scholar
• Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014).
  CAS PubMed PubMed Central Google Scholar
• Inozume, T. et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J. Immunother. 33, 956–964 (2010).
  CAS PubMed PubMed Central Google Scholar
• Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, (2018). This study identifies CD103 and CD39 as markers of tumour-reactive T cells across multiple human cancer types.
• Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
  CAS PubMed PubMed Central Google Scholar
• Singer, M. et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 166, 1500–1511.e9 (2016).
  CAS PubMed PubMed Central Google Scholar
• Gubin, M. M. et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell 175, 1014–1030.e19 (2018).
  CAS PubMed PubMed Central Google Scholar
• Martínez-Usatorre, A., Donda, A., Zehn, D. & Romero, P. PD-1 blockade unleashes effector potential of both high- and low-affinity tumor-infiltrating T cells. J. Immunol. 201, 792–803 (2018).
  PubMed Google Scholar
• Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M. & Kastenmüller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635–647 (2018).
  CAS PubMed Google Scholar
• Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e10 (2019). A mouse study providing evidence for the role of TCF1-expressing PD1 + CD8 + T cells in tumour control on anti-PD1 and anti-CTLA4 combination therapy.
  CAS PubMed Google Scholar
• Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1−CD8+ tumor-infiltrating T cells. Immunity 50, 181–194.e6 (2019). A mouse study that describes a PD1-low subset of T cells that responds to ICB and identifies Tcf7 expression to be required for response to anti-PD1 and anti-TIM3 combination therapy.
  CAS PubMed PubMed Central Google Scholar
• Utzschneider, D. T. et al. T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections. Immunity 45, 415–427 (2016).
  CAS PubMed Google Scholar
• Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421 (2016).
  CAS PubMed PubMed Central Google Scholar
• Wu, T. et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol. 1, eaai8593 (2016).
  PubMed PubMed Central Google Scholar
• Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487–502.e15 (2017).
  CAS PubMed PubMed Central Google Scholar
• Brummelman, J. et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. J. Exp. Med. 215, 2520–2535 (2018).
  CAS PubMed PubMed Central Google Scholar
• LaFleur, M. W. et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat. Immunol. 20, 1335–1347 (2019).
  CAS PubMed PubMed Central Google Scholar
• Wei, S. C. et al. Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states. Immunity 50, 1084–1098.e10 (2019).
  CAS PubMed PubMed Central Google Scholar
• Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447–3452 (2016).
  PubMed PubMed Central Google Scholar
• Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell 35, 238–255.e6 (2019).
  CAS PubMed Google Scholar
• Jiao, S. et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell 179, 1177–1190.e13 (2019).
  CAS PubMed Google Scholar
• Kim, H. J. & Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res. 2, 91–98 (2014).
  CAS PubMed Google Scholar
• Ahrends, T. & Borst, J. The opposing roles of CD4+ T cells in anti-tumour immunity. Immunology 154, 582–592 (2018).
  CAS PubMed Central Google Scholar
• Braumüller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361–365 (2013).
  PubMed Google Scholar
• Qin, L. et al. Insights into the molecular mechanisms of T follicular helper-mediated immunity and pathology. Front. Immunol. 9, 1884 (2018).
  PubMed PubMed Central Google Scholar
• Crotty, S. T follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132–1148 (2019).
  CAS PubMed PubMed Central Google Scholar
• Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765.e17 (2017).
  CAS PubMed PubMed Central Google Scholar
• Giordano, M. et al. Molecular profiling of CD 8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 34, 2042–2058 (2015).
  CAS PubMed PubMed Central Google Scholar
• Li, J., He, Y., Hao, J., Ni, L. & Dong, C. High levels of Eomes promote exhaustion of anti-tumor CD8+ T cells. Front. Immunol. 9, 2981 (2018).
  CAS PubMed PubMed Central Google Scholar
• Chihara, N. et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature 558, 454–459 (2018).
  CAS PubMed PubMed Central Google Scholar
• Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
  CAS PubMed PubMed Central Google Scholar
• Paley, M. A. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220–1225 (2012).
  CAS PubMed PubMed Central Google Scholar
• Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269 (2019).
  CAS PubMed Google Scholar
• Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211–218 (2019).
  CAS PubMed PubMed Central Google Scholar
• Blank, C. U. et al. Defining ‘T cell exhaustion’. Nat. Rev. Immunol. 19, 665–674 (2019).
  CAS PubMed PubMed Central Google Scholar
• Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21 (2019).
  CAS PubMed PubMed Central Google Scholar
• Welch, J. D. et al. Single-cell multi-omic integration compares and contrasts features of brain cell identity. Cell 177, 1873–1887.e17 (2019).
  CAS PubMed PubMed Central Google Scholar
• Stoeckius, M. et al. Simultaneous epitope and transcriptome measurement in single cells. Nat. Methods 14, 865–868 (2017).
  CAS PubMed PubMed Central Google Scholar
• Wang, C., Singer, M. & Anderson, A. C. Molecular dissection of CD8+ T-cell dysfunction. Trends Immunol. 38, 567–576 (2017).
  CAS PubMed PubMed Central Google Scholar
• Philip, M. & Schietinger, A. Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. Curr. Opin. Immunology 58, 98–103 (2019).
  CAS Google Scholar